- Home
- HALO vs VRNA Comparison
HALO vs VRNA Comparison
Compare HALO & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HALO
- VRNA
- Stock Information
- Founded
- HALO 1998
- VRNA 2005
- Country
- HALO United States
- VRNA United Kingdom
- Employees
- HALO N/A
- VRNA N/A
- Industry
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- HALO Health Care
- VRNA Health Care
- Exchange
- HALO Nasdaq
- VRNA Nasdaq
- Market Cap
- HALO 7.6B
- VRNA 8.3B
- IPO Year
- HALO N/A
- VRNA 2017
- Fundamental
- Price
- HALO $76.90
- VRNA $106.43
- Analyst Decision
- HALO Buy
- VRNA Buy
- Analyst Count
- HALO 8
- VRNA 11
- Target Price
- HALO $70.25
- VRNA $114.10
- AVG Volume (30 Days)
- HALO 2.0M
- VRNA 1.3M
- Earning Date
- HALO 10-30-2025
- VRNA 11-03-2025
- Dividend Yield
- HALO N/A
- VRNA N/A
- EPS Growth
- HALO 68.93
- VRNA N/A
- EPS
- HALO 4.37
- VRNA N/A
- Revenue
- HALO $1,178,672,000.00
- VRNA $221,673,000.00
- Revenue This Year
- HALO $32.57
- VRNA $896.59
- Revenue Next Year
- HALO $23.25
- VRNA $77.56
- P/E Ratio
- HALO $17.65
- VRNA N/A
- Revenue Growth
- HALO 34.97
- VRNA N/A
- 52 Week Low
- HALO $42.01
- VRNA $27.54
- 52 Week High
- HALO $77.60
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- HALO 77.94
- VRNA 73.36
- Support Level
- HALO $74.52
- VRNA $106.15
- Resistance Level
- HALO $76.28
- VRNA $106.42
- Average True Range (ATR)
- HALO 1.63
- VRNA 0.20
- MACD
- HALO -0.06
- VRNA -0.16
- Stochastic Oscillator
- HALO 88.60
- VRNA 97.90
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.